Center-Authored Papers

Filters: Author is Mugo, Nelly  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
2009
Lingappa JR, Kahle E, Mugo N, Mujugira A, Magaret AS, Baeten J, Bukusi EA, Cohen CR, Katabira E, Ronald A et al..  2009.  Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study.. PloS one. 4(4):e5272. Abstract
2010
Lingappa JR, Baeten JM, Wald A, Hughes JP, Thomas KK, Mujugira A, Mugo N, Bukusi EA, Cohen CR, Katabira E et al..  2010.  Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial.. Lancet. 375(9717):824-33. Abstract
2011
Baeten JM, Lingappa J, Beck I, Frenkel LM, Pepper G, Celum C, Wald A, Fife KH, Were E, Mugo N et al..  2011.  Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.. The Journal of infectious diseases. 203(1):117-21. Abstract
2012
Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, de Bruyn G, Nakku-Joloba E, Ngure K, Kiarie J et al..  2012.  Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study.. The Lancet infectious diseases. 12(1):19-26. Abstract
Murnane PM, Hughes JP, Celum C, Lingappa JR, Mugo N, Farquhar C, Kiarie J, Wald A, Baeten JM.  2012.  Using plasma viral load to guide antiretroviral therapy initiation to prevent HIV-1 transmission.. PloS one. 7(11):e51192. Abstract
2013
Mugwanya KK, Donnell D, Celum C, Thomas KK, Ndase P, Mugo N, Katabira E, Ngure K, Baeten JM.  2013.  Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis.. The Lancet infectious diseases. 13(12):1021-8. Abstract
Heffron R, Mugo N, Ngure K, Celum C, Donnell D, Were E, Rees H, Kiarie J, Baeten JM.  2013.  Hormonal contraceptive use and risk of HIV-1 disease progression.. AIDS (London, England). 27(2):261-267. Abstract
Murnane PM, Celum C, Mugo N, Campbell JD, Donnell D, Bukusi E, Mujugira A, Tappero J, Kahle EM, Thomas KK et al..  2013.  Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial.. AIDS (London, England). 27(13):2155-60. Abstract
2014
Kahle E, Campbell M, Lingappa J, Donnell D, Celum C, Ondondo R, Mujugira A, Fife K, Mugo N, Kapiga S et al..  2014.  HIV-1 subtype C is not associated with higher risk of heterosexual HIV-1 transmission: a multinational study among HIV-1 serodiscordant couples.. AIDS (London, England). 28(2):235-43. Abstract
Donnell D, Baeten JM, Bumpus NN, Brantley J, Bangsberg DR, Haberer JE, Mujugira A, Mugo N, Ndase P, Hendrix C et al..  2014.  HIV Protective Efficacy and Correlates of Tenofovir Blood Concentrations in a Clinical Trial of PrEP for HIV Prevention.. Journal of acquired immune deficiency syndromes (1999). Abstract
Ndase P, Celum C, Campbell J, Bukusi E, Kiarie J, Katabira E, Mugo N, Tumwesigye E, Wangisi J, Were E et al..  2014.  Successful Discontinuation of the Placebo Arm and Provision of an Effective HIV Prevention Product After a Positive Interim Efficacy Result: The Partners PrEP Study Experience.. Journal of acquired immune deficiency syndromes (1999). 66(2):206-12. Abstract
Heffron R, Donnell D, Kiarie J, Rees H, Ngure K, Mugo N, Were E, Celum C, Baeten JM.  2014.  A Prospective Study of the Effect of Pregnancy on CD4 Counts and Plasma HIV-1 RNA Concentrations of Antiretroviral-Naive HIV-1-Infected Women.. Journal of acquired immune deficiency syndromes (1999). 65(2):231-6. Abstract
Acyclovir
Lingappa JR, Baeten JM, Wald A, Hughes JP, Thomas KK, Mujugira A, Mugo N, Bukusi EA, Cohen CR, Katabira E et al..  2010.  Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial.. Lancet. 375(9717):824-33. Abstract
Baeten JM, Lingappa J, Beck I, Frenkel LM, Pepper G, Celum C, Wald A, Fife KH, Were E, Mugo N et al..  2011.  Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.. The Journal of infectious diseases. 203(1):117-21. Abstract
Lingappa JR, Kahle E, Mugo N, Mujugira A, Magaret AS, Baeten J, Bukusi EA, Cohen CR, Katabira E, Ronald A et al..  2009.  Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study.. PloS one. 4(4):e5272. Abstract
Adult
Lingappa JR, Baeten JM, Wald A, Hughes JP, Thomas KK, Mujugira A, Mugo N, Bukusi EA, Cohen CR, Katabira E et al..  2010.  Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial.. Lancet. 375(9717):824-33. Abstract
Baeten JM, Lingappa J, Beck I, Frenkel LM, Pepper G, Celum C, Wald A, Fife KH, Were E, Mugo N et al..  2011.  Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.. The Journal of infectious diseases. 203(1):117-21. Abstract
Lingappa JR, Kahle E, Mugo N, Mujugira A, Magaret AS, Baeten J, Bukusi EA, Cohen CR, Katabira E, Ronald A et al..  2009.  Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study.. PloS one. 4(4):e5272. Abstract
Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, de Bruyn G, Nakku-Joloba E, Ngure K, Kiarie J et al..  2012.  Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study.. The Lancet infectious diseases. 12(1):19-26. Abstract
Africa
Lingappa JR, Kahle E, Mugo N, Mujugira A, Magaret AS, Baeten J, Bukusi EA, Cohen CR, Katabira E, Ronald A et al..  2009.  Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study.. PloS one. 4(4):e5272. Abstract
Africa, Eastern
Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, de Bruyn G, Nakku-Joloba E, Ngure K, Kiarie J et al..  2012.  Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study.. The Lancet infectious diseases. 12(1):19-26. Abstract
Africa, Southern
Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, de Bruyn G, Nakku-Joloba E, Ngure K, Kiarie J et al..  2012.  Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study.. The Lancet infectious diseases. 12(1):19-26. Abstract
Amino Acid Substitution
Baeten JM, Lingappa J, Beck I, Frenkel LM, Pepper G, Celum C, Wald A, Fife KH, Were E, Mugo N et al..  2011.  Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.. The Journal of infectious diseases. 203(1):117-21. Abstract
Antiviral Agents
Baeten JM, Lingappa J, Beck I, Frenkel LM, Pepper G, Celum C, Wald A, Fife KH, Were E, Mugo N et al..  2011.  Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.. The Journal of infectious diseases. 203(1):117-21. Abstract
Lingappa JR, Baeten JM, Wald A, Hughes JP, Thomas KK, Mujugira A, Mugo N, Bukusi EA, Cohen CR, Katabira E et al..  2010.  Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial.. Lancet. 375(9717):824-33. Abstract